Project Title

An open-label study of Povetacicept in subjects with autoimmune cytopenias (RUBY-4)

Official Title

A phase 1b open-label study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of Povetacicept in subjects with autoimmune cytopenias (RUBY-4).

Project Summary

The goal of this clinical study is to evaluate povetacicept (ALPN-303) in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.

Blood Disorder

• Immune Thrombocytopenia
• Idiopathic Thrombocytopenic Purpura
• Warm Autoimmune Haemolytic Anaemia
• Cold Agglutinin Disease

Patient Recruitment Details

Patient recruitment status: OPEN

Number of patients (Globally)

42